Navigation Links
Defensive measures: Toward a vaccine for Ebola
Date:12/5/2011

On August 26, 1976, a time bomb exploded in Yambuku, a remote village in Zaire, (now the Democratic Republic of the Congo). A threadlike virus known as Ebola had emerged, soon earning a grim distinction as one of the most lethal, naturally occurring pathogens on earth, killing up to 90 percent of its victims, and producing a terrifying constellation of symptoms known as hemorrhagic fever.

Now, Charles Arntzen, a researcher at the Biodesign Institute at Arizona State University, along with colleagues from ASU, the University of Arizona College of Medicine-Phoenix, and the United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, have made progress toward a vaccine against the deadly virus.

The group's research results appear in today's issue of the Proceedings of the National Academy of Science, along with a companion paper by their collaborators at Mapp Pharmaceuticals in San Diego, CA, led by Larry Zeitlin. Arntzen's group demonstrated that a plant-derived vaccine for Ebola provided strong immunological protection in a mouse model.

If early efforts bear fruit, an Ebola vaccine could be stockpiled for use in the United States, should the country fall victim to a natural outbreak or a bioterrorism event in which a weaponized strain of the virus were unleashed on soldiers or the public.

To date, Ebola outbreaks have been mercifully rare. For researchers like Arntzen however, this presents a challenge: "With other lethal viruses like HIV there is a common pattern of occurrence, allowing for vaccine testing. For example, an AIDS vaccine study is now underway at two locations in Thailand, which were chosen because of a current high incidence of the disease."

By contrast, Ebola events are fleeting, episodic and largely unpredictable. For this reason, Arntzen stresses that an Ebola vaccine would most likely not be used prophylacticallythat is, as a means of protecting large populations,
'/>"/>

Contact: Joseph Caspermeyer
Joseph.Caspermeyer@asu.edu
Arizona State University
Source:Eurekalert  

Page: 1 2 3 4 5

Related biology news :

1. Cells die so defensive organs can live
2. Rapid venom evolution in pit vipers may be defensive
3. Toward more cost-effective production of biofuels from plant lignocellulosic biomass
4. Leicester leads the way towards a sustainable lake in Africa
5. Advance toward a breath test to diagnose multiple sclerosis
6. Progress towards developing plants that accommodate climate change
7. Wildlife Conservation Society study uncovers a predictable sequence toward coral reef collapse
8. Award-winning research points toward Alzheimer’s vaccine
9. Another step toward resisting breast cancer
10. Toward new medications for chronic brain diseases
11. Toward a more efficient use of solar energy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Defensive measures: Toward a vaccine for Ebola  
(Date:2/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/sxwl43/global_2d_gesture ... "Global 2D Gesture Recognition Market 2015-2019" report ... forecast the Global 2D Gesture Recognition market to ... period 2014-2019 The increased demand for ... of the major trends in the market. The ...
(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/10/2015)... 10, 2015  Alere Inc. (NYSE: ALR), a ... results for the quarter ended December 31, 2014. ... President of Alere said, "We made substantial progress ... the global leader in rapid diagnostics and delivering ... Health divestiture in early January enabled us to ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2ACT Genomics Raises $8 Million in its First Private Funding Round 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34
... 20 May 2012. The Stem Cells and Cancer Research ... Vall d,Hebrn Institute of Oncology (VHIO) has identified the ... used in clinical trials for colon cancer treatment. The ... with Professor Alberto Muozs laboratory at the Instituto de ...
... PHOENIX, May 18, 2012 /PRNewswire-iReach/ -- With ... out of sight, and research to find "cures" continuing ... remain "a few years away," a small but growing ... human consciousness. A number of healing practices that rely ...
... did not set out to discover one of the longest ... and a team of researchers all current or former ... published in Scientific Reports . Their findings shed ... lead to widespread, yet largely invisible, disruptions of ecological interaction ...
Cached Biology News:Discovery of mechanisms predicting response to new treatments in colon cancer 2Discovery of mechanisms predicting response to new treatments in colon cancer 3Healing Method from Australia Addresses the Human Genome 2Stanford scientists document fragile land-sea ecological chain 2
(Date:2/26/2015)... --  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ) ... 35 th Annual Health Care Conference on Tuesday, March ... .  Lexicon management will provide an overview of Lexicon,s ... the presentation will be available through Lexicon,s website at ... available at www.lexpharma.com until April 3, 2015. ...
(Date:2/26/2015)... SAN FRANCISCO, Calif. , Feb. 26, 2015 /PRNewswire/ ... the treatment of cancer, today announced that Sean ... a corporate overview at the upcoming Cowen and Company ... Boston . Dr. McCarthy,s presentation will take ... About CytomX Therapeutics CytomX Therapeutics develops ...
(Date:2/26/2015)... Caris Life Sciences® today announced the ... Cancers Symposium in Orlando, Fla. ... profiling. Both studies utilized Caris Molecular Intelligence™, the ... biomarkers that shed light on potential treatment strategies ... cancer (SCBC). In one study, ...
(Date:2/25/2015)... Technologies Inc. (TSX-V: RTI) (the "Corporation") announced today that ... quarter of its fiscal year ended March 31, 2015. ... the CEO & CFO certifications for the three and ... on www.SEDAR.com . CFO ... pleased to announce the appointment of Prakash Hariharhan as ...
Breaking Biology Technology:Lexicon To Present At The Cowen 35th Annual Health Care Conference 2Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 2Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 3Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 4Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 5Radient Technologies Inc. Releases Third Quarter Results and Appoints New Interim CFO 2
... Calif., March 9 MannKind Corporation (Nasdaq: ... agreements with Pfizer Inc. (NYSE: PFE ) ... am Main, Germany and assets related to the production ... the production equipment, a quantity of bulk insulin and ...
... March 9 ExonHit Therapeutics (Alternext:,ALEHT) today announced that ... and redeemable November 8, 2011 have been converted,into shares. ... a EUR 17,231 capital increase and EUR,6,982,769 increase in ... debt is reduced to EUR 6,522,178 compared to EUR ...
... March 6 Finesse Solutions, LLC, Santa Clara, CA, ... sciences process applications, announced the technical demonstration of TruFluor(TM) ... Interphex in New York on March 17, 2009.The TruFluor ... of a disposable sheath, an optical reader, and a ...
Cached Biology Technology:MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant 2MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant 3MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant 4ExonHit Therapeutics Shareholders' Equity Strengthened by Exercise of More Than Half of its Convertible Bonds 2Finesse Demonstrates TruFluor(TM) pH, a Single-Use Optical pH Sensor and Transmitter 2